[go: up one dir, main page]

ECSP16024805A - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
ECSP16024805A
ECSP16024805A ECIEPI201624805A ECPI201624805A ECSP16024805A EC SP16024805 A ECSP16024805 A EC SP16024805A EC IEPI201624805 A ECIEPI201624805 A EC IEPI201624805A EC PI201624805 A ECPI201624805 A EC PI201624805A EC SP16024805 A ECSP16024805 A EC SP16024805A
Authority
EC
Ecuador
Prior art keywords
treatment
new compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
ECIEPI201624805A
Other languages
English (en)
Inventor
Robert Chadwick Cummins
Jorge Alsina-Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16024805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP16024805A publication Critical patent/ECSP16024805A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Removal Of Specific Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto útil en el tratamiento de hipoglicemia.
ECIEPI201624805A 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa ECSP16024805A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
ECSP16024805A true ECSP16024805A (es) 2017-02-24

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201624805A ECSP16024805A (es) 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (26)

Country Link
US (1) US9688736B2 (es)
EP (1) EP3083669A1 (es)
JP (1) JP2017503782A (es)
KR (1) KR20160077215A (es)
CN (1) CN105793282A (es)
AP (1) AP2016009268A0 (es)
AR (1) AR098616A1 (es)
AU (1) AU2014366427B2 (es)
BR (1) BR112016012505A2 (es)
CA (1) CA2928987A1 (es)
CL (1) CL2016001473A1 (es)
CR (1) CR20160223A (es)
DO (1) DOP2016000128A (es)
EA (1) EA201691036A1 (es)
EC (1) ECSP16024805A (es)
HK (1) HK1224303A1 (es)
IL (1) IL245399A0 (es)
MA (1) MA39108A1 (es)
MX (1) MX2016007984A (es)
NZ (1) NZ719451A (es)
PE (1) PE20160787A1 (es)
PH (1) PH12016501184A1 (es)
SG (1) SG11201604232TA (es)
TN (1) TN2016000180A1 (es)
TW (1) TW201609129A (es)
WO (1) WO2015094878A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3921336B1 (en) 2019-02-05 2023-03-01 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
CA2786934A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
BR112012024379A2 (pt) * 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
CA2822617A1 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
BR112013024076A2 (pt) * 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
HK1224303A1 (zh) 2017-08-18
SG11201604232TA (en) 2016-07-28
AR098616A1 (es) 2016-06-01
DOP2016000128A (es) 2016-06-30
EP3083669A1 (en) 2016-10-26
PH12016501184A1 (en) 2016-07-25
PE20160787A1 (es) 2016-08-17
MX2016007984A (es) 2016-09-09
AU2014366427B2 (en) 2017-02-16
CL2016001473A1 (es) 2017-03-10
CN105793282A (zh) 2016-07-20
TN2016000180A1 (en) 2017-10-06
JP2017503782A (ja) 2017-02-02
WO2015094878A1 (en) 2015-06-25
NZ719451A (en) 2017-10-27
KR20160077215A (ko) 2016-07-01
AP2016009268A0 (en) 2016-06-30
IL245399A0 (en) 2016-06-30
US9688736B2 (en) 2017-06-27
BR112016012505A2 (pt) 2017-09-26
TW201609129A (zh) 2016-03-16
US20160311883A1 (en) 2016-10-27
EA201691036A1 (ru) 2016-12-30
MA39108A1 (fr) 2017-11-30
CA2928987A1 (en) 2015-06-25
CR20160223A (es) 2016-07-12
AU2014366427A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MX372669B (es) Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
IN2013DE00266A (es)
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
AR097668A1 (es) Colorante-polímero
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DOP2016000067A (es) Nuevo inhibidor de sglt1
BR112015021575A2 (pt) composição fungicida
CL2016000171A1 (es) Formulación de metaxalona.
IN2013MU03768A (es)
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
CL2012000641S1 (es) Lavamanos.
TR201314933A2 (tr) Bakteriyel enfeksiyonların tedavisine yönelik bir kompozisyon.
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه
UA72478U (ru) Применение полентара как средства фригопротекторного действия